Clinical Trial Update: Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]

View source ↗

Summary

Completed clinical trial update evaluating intravenous lansoprazole 30 mg for hemostatic effects and rebleeding rates in gastric and duodenal ulcers and related…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Ulcer
• Gastric Mucosal Lesion
• Gastric Ulcer
• Stress Gastritis

Drugs mentioned

• Lansoprazole Intravenous 30 mg (lansoprazole)

Snippet

Sponsor: Takeda | Conditions: Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions | Status: COMPLETED | Results posted: 2016-02-23